Reference : Innovative Proteomics for the Discovery of Systemically Accessible Cancer Biomarkers ...
Scientific journals : Article
Life sciences : Biochemistry, biophysics & molecular biology
Innovative Proteomics for the Discovery of Systemically Accessible Cancer Biomarkers Suitable for Imaging and Targeted Therapies
Turtoi, Andrei mailto [Université de Liège - ULiège > Département des sciences biomédicales et précliniques > GIGA-R : Labo de recherche sur les métastases >]
De Pauw, Edwin mailto [Université de Liège - ULiège > Département de chimie (sciences) > GIGA-R : Laboratoire de spectrométrie de masse (L.S.M.) >]
Castronovo, Vincenzo mailto [Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie générale et cellulaire >]
American Journal of Pathology
American Society for Investigative Pathology
Yes (verified by ORBi)
[en] The discovery of biomarkers that are readily accessible through the circulating blood and are selectively overexpressed in pathological tissues has become a major research objective, particularly in the field of oncology. Indisputably, this group of molecules has a high potential
to serve as an innovative tool for effective imaging and targeted cancer therapy approaches. In this attractive therapeutic concept, specific cancer proteins are reached by intravenously administered ligands that are coupled to cytotoxic drugs. Such compounds are able to induce cancer destruction while sparing normal tissues. Owing to the performance of mass spectrometry technology, current high-throughput proteomic analysis allows for the identification of a high number of proteins that are differentially expressed in the cancerous tissues. However, such approaches provide no information regarding the effective accessibility of the biomarkers and, therefore, the possibility for these discovered proteins to be targeted. To bypass this major limitation, which clearly slows the discovery of such biomarkers, innovative methodological strategies have been developed to enrich the clinical specimens before the mass
spectrometry analysis. The focus is laid on the group of proteins that are necessarily located either at the exterior face of the plasma membrane or in the extracellular matrix. The present review addresses the current technologies meant for the discovery and analysis of accessible antigens from clinically relevant samples.
Supported by grants from the Research Concerted Action program (IDEA project), from the CEE [FP7 network: ADAMANT-Antibody derivatives as molecular agents for neoplastic targeting (HEALTH-F2-2007-201342)], from the National Fund for Scientific Research (NFSR, Belgium), from TELEVIE, from the Centre Anti-Cancéreux of the University of Liège, and is made in collaboration with the GIGA-Proteomics Platform at the University of Liège, Belgium.
Researchers ; Professionals ; Students

File(s) associated to this reference

Fulltext file(s):

Restricted access
Turtoi et al. AJP-2011-final.pdfAuthor postprint418.38 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.